Michalski, an Amazon alum, and Fergus, ex-CEO of 4Catalyzer, will lead the company creation platform building AI applications in healthcare.NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Ascertain, a healthcare AI company creation platform, today announced the formation of its leadership team with the appointment of CEO Mark Michalski, M.D. and Executive Chairman, Gregg Fergus. Michalski and Fergus will lead Ascertain in its mission to merge deep technical, operational, and clinical expertise to deliver high-quality, equitable, and affordable healthcare.Michalski brings two decades of executive leadership experience to Ascertain. Prior to Ascertain, Michalski led strategic development for healthcare and life sciences at Amazon, was Founding Executive Director at Mass General Brigham/Harvard's Center for Clinical Data Science, and served as President and CMO of two publicly traded companies - Butterfly Network and Hyperfine Research. He is a board-certified radiologist and completed his medical training at Yale and Stanford.Fergus and Michalski met and collaborated closely at the venture studio 4Catalyzer where Fergus was CEO, launching several leading healthcare companies including Butterfly Network, Hyperfine Research, AI Therapeutics, and Quantum Si

Eyetelligence uses AI technology and retinal imaging to screen for eye and other diseases, and will launch in the US as Optain.